Idiopathic Pulmonary Fibrosis | Unmet Need | US/EU | 2022
Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further delay or reverse the disease’s progression, preserve lung function, and prolong survival are sorely needed. The diverse IPF pipeline comprises novel classes including CTGF inhibitors, Rho-associated coiled-coil kinase 2 inhibitors, and agents targeting recombinant human pentraxin-2. In this report, we assess the clinical and commercial opportunities remaining in the IPF space through a comprehensive analysis of surveyed pulmonologists’ treatment drivers and goals and their perception of the performance of key current therapies against these goals.
QUESTIONS ANSWERED
- What are the key treatment drivers and goals for IPF?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies such as Esbriet and Ofev perform on key treatment drivers and goals for IPF?
- What are the key opportunities for drug development in IPF? Where do surveyed pulmonologists perceive the largest gaps in the treatment of IPF patients?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European pulmonologists for a hypothetical new IPF drug?
CONTENT HIGHLIGHTS
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 61 U.S. and 31 European pulmonologists fielded in January 2022.
Key companies: Roche, Boehringer Ingelheim, FibroGen, Promedior / Roche.
Key drugs: Esbriet, Ofev, prednisone.
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
